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Abstract
Background: Sepsis is a severe medical condition that ranks among the top 10 causes of death worldwide and
which has permanently high incidence rates. Mesenchymal stem cells (MSCs) have been found to be potent modulators
of immune responses. More importantly, there is evidence that MSCs have a beneficial effect on preclinical models of
polymicrobial sepsis. However, the changes caused by the MSCs in the effector cells of the host immune system remain
unclear.
Methods: A mouse model of sepsis (male C57BL/6 mice) with three experimental groups was used for
experiments in vivo: a control group, an untreated septic group, and a septic group treated with MSCs. In
vitro experiments were performed using a cell line of pulmonary macrophages (RAW 264.7) co-cultured with
MSCs and stimulated with lipopolysaccharide (LPS).
Results: In vivo we demonstrated that treatment with MSCs was able to reduce the expression of cyclooxygenase-2
(COX-2) and nuclear factor kappa B (NF-κB), and thereby decrease the production of inflammatory cytokines. In vitro
experiments using a co-culture of macrophages with MSCs showed a decrease in COX-2 and NF-κB, and showed that
this reduction was directly related to the ability of MSCs to inhibit phosphorylation of ERK, RSK, and p38, enzymes that
belong to the family of mitogen-activated protein kinases (MAPKs).
Conclusions: This study demonstrated that MSCs are able to inhibit the MAPK pathway activation, modulating the
inflammatory response during sepsis. This understanding that MSCs can remodel the response of host cells and
improve the course of sepsis is essential for developing new treatments for this pathology.
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Background
Sepsis is a severe medical condition that ranks among the
top 10 causes of death worldwide and which has perman-
ently high incidence rates [1]. Even with appropriate anti-
biotic and resuscitative therapies, sepsis carries a 30%
mortality rate and significant morbidity associated with
organ failure [2]. Furthermore, it incurs a staggering $16.7
billion cost in the US health economy, with over 750,000
annual cases and greater than 200,000 deaths each year [3].
Sepsis is caused by an infection and involves a com-
plex interaction between the pathogen and the host
immune cells, characterized by a systemic inflammatory
state [4]. Moreover, the role of the immune response is
crucial to fight infection; it is also responsible for the in-
flammatory tissue infiltration and severe organ damage,
both hallmarks of sepsis [5]. Evidence suggests that
modulation of pro- and anti-inflammatory factors con-
tributes to the suppression of immune effector cells,
induces the systemic inflammation, and causes tissue
damage during the sepsis [6].
Over the last few years, many studies have been con-
ducted in order to decrease the mortality rate associated
with sepsis, but the pharmaceutical research community
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is not getting any substantial new messages regarding
drug design, development, and therapy [7]. However, as
experimental studies have demonstrated in the setting of
sepsis syndrome, mesenchymal stem cell (MSC) treat-
ment notably alleviated the sepsis-induced inflammatory
reaction, decreased mortality, and improved prognostic
outcome [8–12].
MSCs are a subpopulation of multipotent cells that may
be isolated from various adult tissues and organs. Several
studies have described MSCs as a novel therapeutic strat-
egy for the treatment of diseases related to inflammation
and tissue injury because they are potent modulators of
immune system, with the ability to regulate both the innate
and adaptive immune response [13, 14]. Several studies
demonstrate that the protective role of MSCs in sepsis
may be attributed to the soluble paracrine factors released
by these cells, such as interleukin (IL)-10, prostaglandin E2
(PGE2), tumor necrosis factor (TNF)-α and IL-6 [15–17].
Previous studies in experimental model of sepsis dem-
onstrated the ability of MSCs to reprogram macrophages
from a pro-inflammatory state to an anti-inflammatory
state through the release of PGE2, causing increased
secretion of IL-10. Nevertheless, the pathways that are
altered in this reprogramming of effector cells of the im-
mune system are unclear [18].
We know that the cyclooxygenase-2 (COX-2) is re-
sponsible for the production of a huge amount of PGE2,
which is highly expressed during the inflammatory
process [19]. The pathway that usually regulates COX-2
expression in inflammation involves a family of highly
conserved intracellular signaling molecules, the
mitogen-activated protein kinases (MAPKs) [20]. The
MAPK pathway has been implicated in processes regu-
lating cell growth, differentiation, apoptosis, and inflam-
mation. In mammals, there are three MAPK subgroups,
the extracellular signal-regulated kinase (ERK), c-JUN
N-terminal kinases (JNK) and p38 [21].
Therefore, in this study we investigated the ability of
MSCs to decrease COX-2 production and other inflam-
matory mediators through inhibition of the MAPK path-
way. For this purpose we used a model of sepsis
previously developed by our laboratory, consisting of the
introduction of a sterile gelatin capsule in the peritoneal
cavity containing Escherichia coli suspension and non-
sterile fecal content, subsequently followed by an in vitro
investigation using a cell line of lung macrophages, which
are important effector cells of the immune system in-
volved in many immunological reactions.
Methods
Animals
Male C57BL/6 mice (8–12 weeks old) were kept on
shelves in ventilated cages that provide 60 air cycles per
hour, with relative humidity ranging between 55 and
65%, a 12-h light–dark cycle, a temperature of 22 ± 2 °C,
and free access to food and water. The animals were
maintained in accordance with the Guiding Principles in
the Care and Use of Animals approved by the Council of
the American Physiological Society. The experimental
protocol was approved by the Ethics Research Commit-
tee of Pontif ícia Universidade Católica do Rio Grande
do Sul (protocol number 14/00403).
MSC culture and characterization
Male C57BL/6 mice (8–12 weeks old) were MSC
donors. Under sterile conditions, the animals were anes-
thetized (pentobarbital 50 mg/kg intraperitoneally) and,
after the collection of the adipose tissue, mice were
killed by cervical dislocation. In humans, adipose tissue
is usually collected by needle biopsy or liposuction aspir-
ation; for this reason, we chose to perform the collection
of adipose tissue from anesthetized animals and proceed
to euthanasia later. This step makes the work closer to
what happens in the clinic. Adipose tissue was obtained
from the epididymal adipose tissue, cut into small pieces,
collagenase digested, filtered, and then cultured using
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen
Corporation, CA, USA) without ribonucleosides or
deoxyribonucleosides containing 2 mM L-glutamine and
20% fetal bovine serum (FBS; Invitrogen, Carlsbad,
USA), with 1% penicillin–streptomycin. Cells were pas-
saged every 3–4 days by trypsinization when they
reached 70–80% confluence and were used for the
experiments between passages 3 and 4. Between each
passage, cell viability was measured using the trypan
blue exclusion test. MSCs were cultured in a humidified
incubator at 5% CO2 and 37 °C under sterile conditions.
Before each experiment, cells were trypsinized, counted,
washed twice with phosphate-buffered saline (PBS) and
resuspended in PBS. MSCs were characterized by
expression of the cellular markers (CD90+, CD105+,
CD34–, and CD45–), determined by flow cytometry ana-
lysis (Bio-Rad, Hercules, USA). MSCs were induced to
differentiate into adipocytes, osteocytes, and chondro-
cytes using cell differentiation kits from R&D Systems
(Minneapolis, MN, USA) in accordance with the recom-
mendations of the manufacturer.
Experimental sepsis induction and treatment
The animals were weighed and then anesthetized with a
mixture of ketamine (80 mg/kg) and xylazine (20 mg/kg)
intraperitoneally. The abdomen of each animal was
shaved and cleaned with povidone–iodine solution. A 1-
cm midline abdominal incision was made to expose the
linea alba. The peritoneum was opened by blunt dissec-
tion. Sepsis was induced by introducing a sterile gelatin
capsule size “1” in the peritoneal cavity containing
another sterile capsule size “2” with the Escherichia coli
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(3 μL; ATCC 25922) suspension and non-sterile fecal
content (20 mg). This experimental model was devel-
oped by our laboratory [11, 22]. The animals were then
divided into three groups: 1) sham (mice were implanted
with an empty capsule and received a retro-orbital injec-
tion of 100 μL PBS); 2) sepsis (sepsis-induced and
received a retro-orbital injection of 100 μL PBS); and 3)
sepsis +MSCs (sepsis-induced and treated with 1 × 106
MSCs in a retro-orbital injection of 100 μL PBS at the
time of induction). We also used another model of sepsis
induced by the injection of lipopolysaccharide (LPS)
from E. coli 026:B6 (12.5 mg/kg; Sigma-Aldrich, St.
Louis, USA) intraperitoneally. The animals were divided
into the same groups as in the other model. Blood sam-
ples were collected using cardiac puncture 12 h after
sepsis induction. This time was determined from previ-
ous studies in our laboratory.
Histological analysis
The superior lobe of the right lung was ligated and pre-
pared for histological and morphological analysis. Lungs
were perfused with 10% buffered formalin on a gravity
column (20 mmHg). Tissue specimens were embedded
in paraffin blocks, cut into 4-μm sections, stained with
hematoxylin and eosin (H&E), and examined by light
microscopy. Other sections were sequentially subjected
to immunostaining analysis. After deparaffinization, the
sections were sequentially treated with 1% H2O2 for
10 min and rinsed thoroughly with PBS. Sections were
blocked with 2% normal blocking serum in PBS at room
temperature for 60 min to suppress any nonspecific
binding of IgG, followed by incubation with anti-COX2
(dilution 1:200; Merck Millipore, Darmstadt, GER), or
nuclear factor kappa B (NF-κB) p65 (dilution 1:200; Cell
signaling, Danvers, USA). The cellular nuclei were
stained using TO-PRO®3 (dilution 1:1000; Thermo
Fisher Scientific, Waltham, USA). All of the slides were
evaluated by confocal immunofluorescence microscopy.
We calculated the inflammatory lung tissue score using
the software Image-Pro Plus (Medical Cybernetics). The
score for peribronchial and perivascular inflammation
was evaluated on a subjective scale of 0–3, as described
elsewhere [23]. A value of 0 was assigned when no in-
flammation was detectable, a value of 1 was adjudged
for occasional cuffing with inflammatory cells, a value of
2 when most bronchi or vessels were surrounded by a
thin layer (one to five cells thick) of inflammatory cells,
and a value of 3 was given when most bronchi or vessels
were surrounded by a thick layer (more than five cells
thick) of inflammatory cells.
Cytokine quantification
To determine cytokine levels, serum samples were col-
lected from mice 12 h after sepsis induction. Multiple
soluble cytokines (IL-6, TNF-α, IL-10) were simultan-
eously measured using a Luminex Multiplex Assay kit
(Thermo Fisher Scientific). We used a luminometer
Luminex® 100/200 (Luminex Corporation, Austin, USA)
and the results were analyzed using the software xPO-
NENT® Solutions software (Luminex Corporation).
Macrophage stimulation and macrophage–mesenchymal
stem cell co-culture experiments
The RAW 264.7 macrophage cell line was obtained from
Sigma-Aldrich (USA) and grown to confluence in DMEM
containing L-glutamine (2 mM), penicillin (100 IU/mL),
streptomycin (100 mg/mL), and 10% FBS at 37 °C in a 5%
CO2 humidified incubator. Macrophages were plated in
six-well plates at a concentration of 3 × 105 cells in 2 mL
per well. After this, MSCs were also co-cultured in a pro-
portion 1:10 with the macrophages in the same well. After
24 h, macrophages and macrophages co-cultured with
MSCs were stimulated with LPS from E. coli 026:B6
(1 μg/mL; Sigma-Aldrich) at different times.
Western blot analysis
Macrophages or lung tissue were lysed in CHAPS lysis buf-
fer (10 mM Tris–HCl, pH 7.5, 100 mM NaCl, 0.3%
CHAPS, 50 mM NaF, 1 mM sodium vanadate, 1 mM phe-
nylmethylsulfonyl fluoride, 5 μg/mL leupeptin, 5 μg/mL
aprotinin, 1 μg/mL pepstatin A, 50 mM β- glycerophos-
phate, 100 μg/mL benzamidine) for 30 min at 4 °C and
equal amounts of proteins were separated by electrophor-
esis. We used Tris-Acetate PAGE systems as previously de-
scribed [24, 25]. After running the gel, the proteins were
transferred to PVDF membranes and viewed by immuno-
blotting, as described elsewhere [23, 24]. Band intensities
were analyzed with a gel documentation system (LAS-3000
Fujifilm). The levels of phosphorylated proteins (p-p38,
pERK1/2, and pRSK) were standardized with relative levels
of their total amount. COX-2 and NF-kB were standardized
with respect to GAPDH levels and all was expressed as a
percentage of controls. We used the following antibodies
for the experiments: anti-COX-2 (1:1000 dilution; Merck
Millipore, Darmstadt, GER), NF-κB p65 (1:1000 dilution),
phospho-ERK1/2 (1:1000 dilution), phospho-p38 (1:1000
dilution), phospho-RSK (1:1000 dilution; Cell signaling,
Danvers, EUA), total ERK1/2 (1:1000 dilution; Aviva
Systems Biology, San Diego, USA), p38 (1:1000 dilution;
Santa Cruz Biotechnology, Santa Cruz, USA), RSK (1:1000
dilution; Cell Signaling Technology), and anti-GAPDH
(1:3000 dilution; Sigma-Aldrich).
Quantitative real-time polymerase chain reaction (PCR)
analysis
Macrophages were prepared and subjected to RNA iso-
lation using TRIsure Reagent (Bioline), followed by re-
verse transcription to cDNA. cDNA was synthesized
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using a cDNA reverse transcription kit. Quantitative
PCR amplification reactions were performed with Taq-
Man® PCR Master Mix (Invitrogen Life Technologies,
Massachusetts, USA) according to the manufacturer’s in-
structions. Quantitative PCR amplification reactions
were performed in the 7500 Fast Real-Time PCR System
(Applied Biosystems). The following pre-designed Taq-
Man assays were used: GAPDH (Mm99999915_g1), IL-
1β (Mm00434228_m1), IL-6 (Mm00446190_m1), IL-10
(Mm00439616_m1), and COX-2 (Mm00478377_g1).
Values were normalized to GAPDH expression.
Cell culture and transfection
The mouse COX-2 promoter-luciferase construct pCOX-
511, NF-κB promoter-luciferase construct pNFKB-Luc+
(Stratagene), and pSV40-β-galactosidase control vector
(Promega) were generous gifts from Dr. Francesc Ventura
(Universitat de Barcelona). Cells were transfected using
Lipofectamine LTX (Invitrogen), and after 6 h the treated
group was co-cultivated with MSCs. The next day, cells
were serum starved before reaching confluence and
treated with LPS (1 μg/mL; Sigma-Aldrich) for 24 and
48 h. Luciferase activities were quantified using the lucif-
erase assay system (Promega, Madison, WI, USA). Lucif-
erase values were normalized using β-galactosidase, and
activity measured with the Luminescent β-Galactosidase
Detection Kit II (CLONTECH, Palo Alto, CA, USA).
Statistical analysis
The data were analyzed by one-way analysis of variance
(ANOVA) or Student’s t test. For comparison of
significance, Tukey’s test was used as a post-hoc test
according to the statistical program GraphPad Prism.
Quantitative data are presented as means ± SEM. Differ-
ences were considered significant at p < 0.05.
Results
MSC administration ameliorates inflammation on sepsis in
the lung
As a first step, we used two models of sepsis induction
in mice to verify the ability of MSCs to decrease pul-
monary inflammation. When we performed H&E stain-
ing 12 h after sepsis induction, it was observed that
induction using only LPS was not able to cause inflam-
mation in the lung. In contrast, sepsis induction
performed with the capsule model, previously standard-
ized by our laboratory, was able to cause an increase in
lung cell infiltrates (Fig. 1a).
We calculated the score for inflammatory lung tissue
using the software Image-Pro Plus (Medical Cybernet-
ics). It was possible to evaluate in the septic group that
there was an increase in the inflammatory score, both
peribronchial and perivascular, when compared with the
sham group. The MSC-treated group had a reduced
score when compared with the septic group, demon-
strating the ability of MSCs to decrease inflammation in
the lung tissue (Fig. 1b).
In previous studies from our laboratory, using this same
model, we observed a decreased production of
inflammatory cytokines [11]. In the present study, we mea-
sured the concentration of two inflammatory markers, IL-6
and TNF-α, and one anti-inflammatory marker, IL-10, in
Fig. 1 Mice treated with MSCs showed a reduced inflammation score in the lung. a Lung sections were subjected to H&E staining. b The inflammatory cells
that infiltrated into the peribronchial and perivascular lung tissues in the sepsis group were ameliorated after MSC administration (×200 magnification). Data
represent the mean ± SEM, n = 5. ###p < 0.001, sham versus sepsis group; ***p < 0.001, sepsis versus sepsis + MSC group. LPS lipopolysaccharide;
MSC mesenchymal stem cell
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Fig. 3 MSC administration reduced elevated COX-2 in lung tissue. a Lung sections were prepared, and immunofluorescence was used to assess
the expression of cyclooxygenase-2 (COX-2; green) using a fluorescence microscopy. TO-PRO 3-staining nuclei (blue) were also shown. Images
show representative data from one of four individual experiments. The COX-2 levels in lung tissue were measured by immunohistochemistry
assay. There was a significant increase in COX-2 protein in the sepsis group compared with the sham group. COX-2 expression was decreased in
the sepsis + mesenchymal stem cell (MSC) group compared with the LPS group (n = 5 per group, ×100 magnification). b Lung tissues were
scraped into a homogenate and analyzed by Western blotting for the expression of COX-2. COX-2 expression was increased in the sepsis group
and decreased after MSC administration. Data represent the mean ± SEM, n = 5. ###p < 0.001, versus the sham group; ***p < 0.001, versus the
sepsis group
Fig. 2 Mice treated with MSCs show reduced inflammatory markers. The pro-inflammatory factors tumor necrosis factor-alpha (TNF-α) and
interleukin-6 (IL-6), and the anti-inflammatory factor IL-10 in the serum were detected by luminescence. The serum showed a significant increase
in IL-6 (a) and TNF-α (b) in the sepsis group compared with the levels in the sham group. A significant decrease in TNF-α and IL-6 was observed
in the sepsis + mesenchymal stem cell (MSC) group compared with the levels in the sepsis group. Furthermore, the serum showed a significant
increase in IL-10 (c) in the sepsis group compared with the levels in the sham group, and a greater increase in the sepsis + MSC group when
compared with the septic group. Data represent the mean ± SEM, n = 10. ###p < 0.001, versus sham group; **p < 0.01, ***p < 0.001, versus sepsis group
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serum. IL-6 and TNF-α were significantly increased in the
sepsis group compared with the sham group, and this
increase was reduced in the sepsis group treated with
MSCs (Fig. 2a and b). Furthermore, the group that
received MSCs had a greater increase in IL-10 than the
untreated sepsis group (Fig. 2c). These results demon-
strate the anti-inflammatory potential of these cells.
MSCs attenuate COX-2 and NF-κB expression in lung tissue
COX-2 is overexpressed in response to inflammatory
inducers and this increase is responsible for the produc-
tion of various factors involved in the inflammatory
process [26]. Thus, we investigated whether MSCs
during sepsis were able to decrease the expression of
COX-2 in lung tissue. First, we performed immunofluor-
escence staining and made a comparison between the
groups. We saw an increase in the sepsis group com-
pared with the control group. However, this increase
was not observed in the sepsis group that received treat-
ment with MSCs (Fig. 3a). To confirm that COX-2
expression was really reduced in the group treated with
MSCs, we performed a Western blot and again observed
a decrease in the treated group when compared with the
untreated sepsis group (Fig. 3b).
We also investigated if there was a reduction in the
expression of NF-κB, which is a transcriptional regulator
and induces the expression of several genes including
COX-2. When we performed immunofluorescence stain-
ing, we observed that the sepsis group had increased
NF-κB compared with the control group, and that this
increase was reduced on treatment with MSCs (Fig. 4a).
We also conducted Western blotting to confirm this
decrease. The increase in NF-κB expression in the MSC-
treated group is significantly reduced when compared to
the sepsis group (Fig. 4b).
LPS-induced pERK, pRSK, p-p38, and NF-κB upregulation
in the macrophage cell lines
Macrophages are directly involved in inflammation and
are responsible for the release of several cytokines and
Fig. 4 MSC administration reduced elevated NF-κB in lung tissue. a Lung sections were prepared, and immunofluorescence was used to assess
the expression of NF-κB (green) using a fluorescence microscopy. TO-PRO 3-staining nuclei (blue) were also shown. Images show representative
data from one of four individual experiments. The NF-κB levels in lung tissue were measured by immunohistochemistry assay. There was a significant
increase in NF-κB protein in the sepsis group compared with the sham group. NF-κB expression was decreased in the sepsis +mesenchymal stem cell
(MSC) group compared with the LPS group (n = 5 per group, ×100 magnification). b Lung tissues were scraped into a homogenate and analyzed by
Western blotting for the expression of NF-κB. NF-κB expression was increased in the sepsis group and decreased after MSC administration.
Data represent the mean ± SEM, n = 5. ###p < 0.001, versus the sham group; ***p < 0.001, versus the sepsis group
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increased COX-2 expression [27]. To investigate the pos-
sible mechanism by which MSCs can reduce lung inflam-
mation during sepsis, we performed in vitro experiments
using a cell line of pulmonary macrophages (RAW 264.7)
stimulated with LPS. We know that the principal route of
activation of COX-2 production and other inflammatory
cytokines such as TNF-α and IL-1 occurs via the MAPK
pathways, so we attempted to verify that this could be a
potential mechanism of action of the MSCs.
First, we performed a time-course experiment to evalu-
ate the best activation times of these proteins by Western
blot. We tested the phosphorylation of p38, ERK1/2, and
RSK, which is a substrate of ERK, and the NFκB expres-
sion. The best activation times were concentrated between
5 min and 24 h, so we chose three times—15, 30, and
60 min—for the following experiments (Fig. 5).
LPS-induced pERK, pRSK, p-p38, and NF-kB expression is
reduced in macrophages co-cultured with MSCs
To investigate if the MSCs were able to reduce the acti-
vation induced by LPS, we co-cultivated macrophages
with MSCs. Macrophages were co-cultured for 24 h with
the MSCs and, afterwards, were treated with LPS
according to the predefined times. NF-κB and p-RSK
were reduced in the RAW+MSC group when compared
with the group exposed to LPS without co-cultivation at
all times (Fig. 6a and d). Macrophages co-cultured with
MSCs had decreased phosphorylation of p-p38 and p-
ERK at 15 and 30 min compared to the RAW group
stimulated with LPS (Fig. 6b and c).
We included a group with only stem cells (without co-
culture with macrophages) to demonstrate that there is
no influence or background expression from the MSCs,
and the results show that the expression of proteins
studied comes only from macrophages (Fig. 7). We per-
formed these Western blot experiments using propor-
tionally 10% of the amount of protein used in the co-
cultivated group, since in the RAW+MSC group the
cells are plated proportionally at 10:1.
To confirm our findings by Western blot, we performed
immunofluorescence staining in all groups for p-p38, p-
ERK1/2, p-RSK, and NF-κB. Our results showed the same
profile found from the Western blot. It was shown that
co-cultivation with MSCs inhibited NF-κB expression and
the phosphorylation of p-38, ERK1/2, and RSK when com-
pared with the group that had only induction with LPS.
All these results demonstrate the ability of these cells to
prevent the activation of the MAPK pathway that is essen-
tial for inflammation (Fig. 8).
Macrophage cell lines co-cultured with MSCs prevent LPS-
induced COX-2 and NF-kB expression over the long-term
We wanted to know if the inhibition of phosphorylation
in the MAPK pathways caused by MSCs could affect the
Fig. 5 LPS-induced MAPK pathway activation. We performed a time-course experiment to evaluate the best times for the MAPK pathway activation.
Macrophages were cultured with or without LPS (1 μg/mL) for 5, 15, 30, and 60 min and 3, 6, 12, and 24 h. Protein expression was evaluated using
Western blot analysis. LPS induced a significant increase in the expression of (a) p-RSK, (b) p-p38, (c) p-ERK, and (d) NF-κB at different
times. Data represent the mean ± SEM, n = 5. *p < 0.05, **p < 0.01, ***p < 0.001, versus sham
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expression of COX-2 and NF-κB over the long term,
maintaining the anti-inflammatory effect. Thus, we
transfected macrophages with a COX-2 promoter-
luciferase construct and NF-κB promoter-luciferase con-
struct separately. According to the analysis of luciferase
activity, we observed a significant increase at 24 h and
48 h in the group treated with LPS compared with the
control group for both COX-2 and NF-κB promoter
activity. This increase was not observed in the group co-
cultured with MSCs. This result indicates that a possible
initial inhibition of phosphorylation of MAPKs by MSCs
can lead to inhibition of COX-2 and NF-κB over the long
term, and demonstrates the ongoing anti-inflammatory
potential of the MSCs (Fig. 9).
MSCs attenuate LPS-induced IL-1, IL-6, and COX-2, and
promote IL-10 expression in macrophages
The macrophages exposed to LPS for 24 h with and
without co-culture were collected for analysis by quanti-
tative PCR of the mRNA levels of IL-1, IL-6, IL-10, and
COX-2. The group treated with LPS had a significant
increase in IL-1 at 12, 24, and 48 h. At 48 h, we saw an
IL-6 increase in the sepsis group when compared with
the control group. In all cases, co-culture with MSCs
was able to significantly reduce this increase (Fig. 10a
and b). The levels of the anti-inflammatory cytokine IL-
10 increase in the groups treated with LPS at 12, 24, and
48 h, and MSCs provoked a significant increase when
compared to the group treated with LPS at 24 h
(Fig. 10c). COX-2 levels are increased in the LPS groups
at all times, and the MSCs induced a significant reduc-
tion at 24 and 48 h (Fig. 10d).
MAPK p38 and ERK signaling is required for MSC-
mediated LPS-induced COX-2 and NF-κB expression in
macrophages
Subsequently, we attempted to prove that the activation
of p38 and ERK has an important role in the upregula-
tion of COX-2 and NFκB, and the effects seen on treat-
ment with MSCs possibly occur through this pathway.
We measured the expression of COX-2 and NFκB using
a specific inhibitor for p38, SB203580, and another for
ERK, U0126. Macrophages previously transfected with
the reporter genes were treated with inhibitors and
Fig. 6 Co-cultivation with MSCs inhibited LPS-induced phosphorylation of RSK, p38, ERK, and NF-κB expression in macrophages. Macrophages
were treated with LPS (1 μg/mL) for 15, 30, and 60 min. The MAPK phosphorylation and NF-κB expression were evaluated by Western
blot analysis. a RSK was phosphorylated at 15, 30, and 60 min in response to LPS. The co-culture with mesenchymal stem cells (MSCs)
inhibited the activation-associated phosphorylation of RSK at all times. b p38 phosphorylation was increased in the macrophages treated
with LPS after 15, 30, and 60 min, and decreased upon co-cultivation with MSCs at 15 and 30 min. c ERK was phosphorylated after 15
and 30 min in response to LPS stimulation and this phosphorylation could be inhibited by co-cultivation with MSCs. Blots are representative of at least
four separate experiments. d NF-κB expression was increased in the LPS group after 15, 30, and 60 min. This increase was inhibited by MSCs at all
times. Data represent the mean ± SEM, n= 5. ##p < 0.01, ###p< 0.001, versus corresponding untreated controls; *p< 0.05, **p< 0.01, versus corresponding
RAW counterparts
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subsequently subjected to LPS for 24 and 48 h. We
observed a decrease in the promoter activity of COX-2
and NF-κB with both inhibitors when compared with
the group treated with LPS (Fig. 11). We also measured
a group using both inhibitors at the same time to verify
any synergistic effect, but none was found. These data
suggest that MSCs can decrease COX-2 and NF-κB
expression via the MAPK pathway, p38 and ERK,
thereby modulating the inflammation.
Discussion
In this study we evaluated the effect of MSC therapy in
a sepsis model and its possible mechanism of action in
pulmonary macrophages. Our study suggests that MSC
injection into a sepsis model can improve the inflamma-
tion acting via inhibition of the MAPK pathway by gen-
erating decreased production of inflammatory mediators.
Sepsis is defined by a generalized inflammation due to
a host immune disorder, dysregulation of the clotting
cascade, and endothelial dysfunction in response to the
invading pathogenic agents [28]. This can progress to
septic shock, generating significant dysfunction of mul-
tiple organs and potentially resulting in death. Over the
past years, several studies have shown the ability of
MSCs to attenuate the dysfunction of organs and
improve survival in several models of sepsis in animals,
suggesting its potential use for treatment of patients
with sepsis [11, 16, 29, 30]. MSCs have an intrinsic cap-
acity to migrate to injured tissues, such as the lung,
myocardium, brain, liver, and kidney, and can improve
the lesion by reducing both local and systemic inflam-
mation via a decrease in the production of pro-
inflammatory cytokines and an increase in production of
anti-inflammatory cytokines [31, 32]. In this study, we
demonstrated a possible immunomodulatory mechanism
of MSCs through this process.
First, we evaluated two models in vivo to identify
which would have a greater inflammatory score and
which we should use to study the possible mechanism of
action of MSCs on the inflammatory response. Our evi-
dence showed that the severe sepsis model developed by
our laboratory was a better way, and we thus performed
in vivo experiments with this model.
Sepsis causes multiple organ dysfunction, including
the cardiovascular system, liver, kidney, and lung. Fifty
percent of patients with severe sepsis will develop acute
Fig. 7 An MSC fraction directly co-cultivated without macrophages does not influence the results found in the Western blot. a We analyzed whether the
protein expression of MAPKs and NF-κB found in Western blot could be due to the mesenchymal stem cells (MSCs). We did not observe any expression
from the MSCs alone. b Representative image of co-cultivation between macrophages and MSCs
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lung injury (ALI) and it is generally considered that
damage to the lung is one of the most severe outcomes
of sepsis [33]. It was observed that intravenous MSC
administration attenuated the score of lung inflamma-
tion in our study.
MSCs display some immunosuppressive characteristics
that may be quite important in sepsis [34, 35]. Soluble para-
crine signals from MSCs have been shown to downregulate
inflammatory cytokine production by macrophages and
inhibit neutrophil chemotaxis [36]. When we analyzed the
interleukin levels in the serum of the animals, we observed
a reduction in inflammatory cytokines IL-6 and TNF-α,
and an increase in the production of the anti-inflammatory
IL-10, corroborating previous studies [11, 18].
Sepsis is a systemic inflammatory response against
bacterial agents. This inflammatory response is charac-
terized by increased inflammatory cytokines TNF- α, IL-
1, and IL-6, and anti-inflammatory cytokines, especially
IL-10 [37]. Activation of MSCs by pro-inflammatory fac-
tors triggers two paracrine negative feedback loops that
can reduce inflammation. The first loop involves
PGE2, as demonstrated in a study by Németh et al.
[18] using a model of sepsis in mice induced by cecal
ligation and puncture. In the same study, in in-vitro
experiments, MSCs were shown to secrete PGE2 in
response to endotoxin (LPS). PGE2 altered the activ-
ity of tissue-resident macrophages with a pro-
inflammatory response and stimulated the secretion
of an array of anti-inflammatory mediators such as
IL-10 and IL-1 receptor antagonist, reducing the sys-
temic effects of sepsis and thus improving survival
[18]. However, although these results demonstrate
that MSCs reprogram macrophages, how this occurs
remained uncertain.
Fig. 8 Immunohistochemistry analysis of the expression of pRSK, p-p38, p-ERK, and NF-κB in macrophages. Macrophages were prepared and im-
munofluorescence was used to assess the expression of (a) pRSK, (b) p-p38, (c) p-ERK, and (d) NFκB using fluorescence microscopy. TO-PRO-3-
staining nuclei (blue) are also shown. Images show representative data from one of four individual experiments. pRSK, p-p38, p-ERK, and NF-κB
expression increased in the macrophages treated with LPS when compared with the untreated group. This increase was reduced in the group
co-cultured with mesenchymal stem cells (MSCs). n = 5, ×20 magnification
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COX-2 is transiently induced after mitogenic or in-
flammatory stimuli, implicating it in the production of
prostaglandins involved in inflammatory responses [38].
Our in vivo results showed that administration of MSCs
could decrease COX-2 production following sepsis in-
duction. This led us to seek a possible mechanism of ac-
tion in vivo in macrophages to justify this inhibition
found in the in vivo model.
The pathway that usually regulates COX-2 expression
in inflammation involves a family of highly conserved
intracellular signaling molecules, the MAPKs [39]. Gen-
erally, ERK1/2 responds to mitogens and growth factors
that regulate cell proliferation and differentiation,
whereas p38 is activated by environmental stresses, such
as UV radiation, heat shock, and pro-inflammatory cyto-
kines such as IL-1 and TNF-α [21].
We selected macrophages, which are the predominant
immune effector cells, to act as mediators of the inflam-
matory response and which contribute to both the initi-
ation and resolution of inflammation [40]. First, we
evaluated if LPS was effective in activating the MAPK
pathway, and we chose short time points since we saw
with those a better activation response. When we co-
cultivated macrophages with MSCs we observed a sig-
nificant reduction in phosphorylation and that a possible
route of action of the MSCs was via the MAPK pathway.
This phosphorylation-inhibition mechanism of MSCs on
the MAPK pathway is poorly described. Recent studies
Fig. 10 MSCs attenuated LPS-induced IL-1, COX-2, and IL-6 production, and promoted IL-10 production in macrophages. Macrophages were cultured
with or without mesenchymal stem cells (MSCs) with LPS (1 μg/mL) for 12, 24, and 48 h, and were subjected to real-time PCR analysis. LPS significantly
increased the (a) interleukin (IL)-1 (12, 24, and 48 h), (b) IL-6 (48 h), and (d) cyclooxygenase-2 (COX-2) (12, 24, and 48 h) when compared with the control
group. In the group co-cultivated with MSCs, the mRNA levels of IL-1, IL-6, and COX-2 decreased significantly when compared with the respective LPS
group, while (c) the IL-10 mRNA levels increased significantly at 24 h compared with the LPS group. Data represent the mean ± SEM, n= 5. ##p< 0.01,
###p < 0.001, versus corresponding untreated controls; *p < 0.05, **p < 0.01, ***p < 0.001, versus corresponding RAW counterparts
Fig. 9 Induction of COX 2 and NF-κB expression over the long term is reduced by co-cultivation with MSCs. Macrophages were transfected with
plasmids as described in the Methods section to evaluate the expression of COX 2 and NF-κB. Macrophages were then co-cultivated or not with
mesenchymal stem cells (MSCs), and stimulated with LPS. The induction fold was determined and the luciferase activity was normalized to the β-
galactosidase activity. a NF-κB expression increased in the macrophages treated with LPS when compared with the untreated group at 24 and
48 h. This increase is reduced in the group co-cultured with MSCs. b There was a significant increase in COX-2 protein expression in the group
treated with LPS when compared with the untreated group at 24 and 48 h. This increase was inhibited by co-cultivation with MSCs. Data represent the
mean ± SEM, n= 5. ##p< 0.01, ###p < 0.001, versus corresponding untreated controls; **p < 0.01, ***p < 0.001, versus corresponding RAW counterparts
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using a model of cigarette smoke induction showed
results similar to the findings in our research [39].
Recent studies have shown that MAPKs can bind to
and stimulate kinase targets, translocate to the nucleus,
and activate NF-κB transcription [41]. The ability of
MSCs to inhibit the MAPK pathway by co-cultivation is
essential for inhibiting the production of NFκB and sub-
sequently the production of other inflammatory media-
tors. This factor regulated inflammatory cytokines,
mainly IL-1, IL-6, and TNF-α. As is seen in the in vivo
experiments, NF-κB expression in vitro is also reduced.
Continuing this work, we attempted to investigate if
this inhibition profile of COX-2 and NF-κB remained
over a longer period of time, and if somehow it could
still have an effect on the production and release of pro-
and anti-inflammatory factors derived from macro-
phages. When we transfected the macrophages with a
reporter gene for COX-2 and NF-κB we observed that
this decrease was maintained in the group co-cultured
with MSCs. In addition, mRNA levels of pro-
inflammatory cytokines IL-1 and IL-6 were higher than
in the group co-cultured with MSCs; however, the
increase in the anti-inflammatory IL-10 was significantly
higher in the co-cultured cells. This shows that the
reduction of inflammatory mediators and reprogram-
ming of macrophages caused by MSCs was possibly
through the MAPK pathway.
Furthermore, we wanted to show that the action of
MSCs was via the MAPK pathway. Thus, we used two
specific inhibitors, one for p38 and another for ERK.
When we performed an analysis of COX-2 and NF-κB
levels, the results showed that both inhibitors were able
to inhibit the production of both NF-κB and COX-2,
showing a similar profile to that found when macro-
phages were co-cultured with MSCs. Altogether, these
results suggest that the reduced production of inflamma-
tory mediators caused by MSCs comes from their ability
to inhibit the MAPK pathway which would cause a de-
crease in production of COX-2, NF-κB, and other in-
flammatory mediators during sepsis.
Conclusions
Our study was able to show that the immunomodulatory
effect of MSCs is directly related to their ability to in-
hibit the activation of MAPKs such as ERK, RSK, or
p38, causing a decrease in the production of COX-2 and
NF-κB, and therefore inflammatory cytokines. The way
that MSCs act and are able to influence the host re-
sponse is essential for an understanding in the search for
new alternative treatments for sepsis.
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